Bayer’s Vividion emerging as significant player in San Diego Biotech hub
Bayer now present in four of the largest biotechnology hubs in the United States
Bayer now present in four of the largest biotechnology hubs in the United States
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
CerTest Biotec uses the BD MAX molecular diagnostic system open system reagent suite to develop RT-PCR detection kit
The second phase of the orientation workshop is being organized to provide in-depth knowledge to the state officials on core building blocks of ABDM
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
A research group led by Ben-Gurion University of the Negev managed to produce an innovative microchip for creating sperm in a culture by using a microfluidic system.
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Govt. has set a target to increase the number of JanAushadhi Kendras to 10,000 by March 2024
Subscribe To Our Newsletter & Stay Updated